The immune tolerance network: a new paradigm for developing tolerance-inducing therapies.

  title={The immune tolerance network: a new paradigm for developing tolerance-inducing therapies.},
  author={Daniel Rotrosen and Jeffrey B. Matthews and Jeffrey A. Bluestone},
  journal={The Journal of allergy and clinical immunology},
  volume={110 1},
Immune tolerance therapies are designed to reprogram immune cells in a highly specific fashion to eliminate pathogenic responses while preserving protective immunity. A concept that has tantalized immunologists for decades, the development of tolerance-inducing therapies, would revolutionize the management of a wide range of chronic and often debilitating diseases by obviating the need for lifelong immunosuppressive regimens. The advances of the past decade have provided a more detailed… 

Figures from this paper

The immunological monitoring of alloreactive responses in liver transplant recipients: A review
The aim of this work is to review the current knowledge in the field of immunological monitoring of allogenic responsiveness in clinical liver transplantation and propose promising candidate assays for the detection of post‐transplant immune deviation, of circulating precursors of dendritic cells subtypes, and of regulatory T cells.
Frontiers in nephrology: immune tolerance to allografts in humans.
  • R. Girlanda, A. Kirk
  • Medicine, Biology
    Journal of the American Society of Nephrology : JASN
  • 2007
An overview of the existing, largely anecdotal, clinical experience with organ allograft tolerance is provided and the various approaches that are being applied in pilot human trials are reviewed and avenues for future clinical investigation are suggested.
Transplantation tolerance in pediatric recipients: Lessons and challenges
Mechanisms of self and transplantation tolerance, translation of basic science research to clinical protocols in animals and human beings, the changing role of immunosuppression, complications following tolerance induction and controversies surrounding the choice of patients for tolerance trials are reviewed with a focus on issues relevant to pediatric patients.
Tolerance induction in clinical transplantation: the pending questions
The key questions that these trials will have to address are discussed, including the induction of central tolerance by establishment of mixed chimerism through hematopoietic stem cell transplantation and the inductionof “operational tolerance” through immunodeviation involving dendritic or regulatory T cells.
New take on comparative immunology: relevance to immunotherapy.
It is proposed that a similar strategy could be applied to searching for themes shared by distinct immune pathologies within the authors' own species, uncovering essential mechanisms that may represent universal targets for immunotherapy.
The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity
The role of the ICOS in parasitic and viral infections, asthma, autoimmunity, transplantation immunology, and tumor surveillance, the third costimulatory molecule for which a human disease has been described, is discussed.
Overview of Immunity
It is important that the immune effector mechanisms that are operative during hypersensitive responses are identical to the mechanisms that occur during appropriate and protective immune responses in other circumstances.
T-Cell Maturation and Activation
The structure of the thymus provides an environment where immature thymocytes can interact with a variety of cells, including thymic epithelial cells and dendritic cells, to acquire their final


Transplantation tolerance: mechanisms and strategies?
This article will focus on the mechanism of T cell tolerance and how the immune system may be manipulated to achieve tolerance to alloantigens.
Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms.
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.
Findings suggest that CD3 antibodies can be engineered to lose their toxicity while retaining their potency as immunosuppressants in the management of transplant patients and in therapy of autoimmune diseases.
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
These studies identify a previously unknown T-cell co-stimulatory pathway as a potential therapeutic target and isolate a mouse homolog of human LIGHT, a member of the tumor necrosis factor (TNF) ‘superfamily’.
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
It is concluded that CTLA4-Ig and 5C8 can both prevent and reverse acute allografted rejection, significantly prolonging the survival of major histocompatibility complex-mismatched renal allografts in primates without the need for chronic immunosuppression.
Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts.
Results with anti-CD3-IT show promise for development of cadaver transplant tolerance induction, especially in outbred, major histocompatibility complex-incompatible donor-recipient pairs with high pretransplant mixed lymphocyte response and cytotoxic T lymphocyte precursor activity.
An Inherited Disorder of Lymphocyte Apoptosis: The Autoimmune Lymphoproliferative Syndrome
The autoimmune lymphoproliferative syndrome (ALPS) represents a failure of apoptotic mechanisms that help maintain normal lymphocyte homeostasis, with a consequent accumulation of lymphoid mass and persistence of autoreactive cells.
Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients.
The antibody Campath 1H with a unique target CH52 on T & B lymphocytes and monocytes has been used to eliminate lymphocytes from the blood for a month in patients with renal allografts who have then been maintained on half dose Cyclosporin without any other maintenance drug.
LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1
It is demonstrated that LIGHT is selectively expressed on immature dendritic cells (DCs) generated from human PBMCs, and engagement of LIGHT costimulates human T cell proliferation, amplifies the NF-κB signaling pathway, and preferentially induces the production of IFN-γ, but not IL-4, in the presence of an antigenic signal.
Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154.
Clinical islet cell transplantation has resulted in insulin independence in a limited number of cases. Rejection, recurrence of autoimmunity, and impairment of normal islet function by conventional